Academic Journals Database
Disseminating quality controlled scientific knowledge

The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension

Author(s): Sean Gaine | Gérald Simonneau

Journal: European Respiratory Review
ISSN 0905-9180

Volume: 22;
Issue: 130;
Start page: 487;
Date: 2013;
Original page

Assessment of change in exercise capacity using the 6-min walk distance (6MWD) test has been the primary end-point in the majority of pulmonary arterial hypertension (PAH) clinical trials. The 6MWD has some advantages as an end-point in such studies. It is simple and inexpensive to perform, reproducible and validated. In short-term studies with small patient numbers, as is typical in a rare disease like PAH, using change from baseline in 6MWD as the primary outcome measure demonstrated statistically significant differences between placebo and study drugs, leading to their approval. However, there have been increasing calls for clinical trials to employ primary end-points that reflect long-term disease progression and morbidity. While the 6MWD was initially considered to be a potentially reliable surrogate for disease progression in PAH, there is increasing evidence that this is not necessarily the case. Given this, there is a need to re-examine the role of 6MWD in PAH trials, and to evaluate the evidence supporting whether there is a need to move from 6MWD to more robust measures of clinical outcomes, such as morbidity and mortality. However, in the clinic the 6MWD test, alongside symptoms, haemodynamics and biomarkers, remains a useful tool in the assessment and management of PAH patients.

Tango Rapperswil
Tango Rapperswil


HR software für Hotellerie

Automatische Erstellung
von Personaldokumente
und Anmeldungen bei Behörden